Latest Disease-modifying antirheumatic drug Stories
A recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors.
Patients with rheumatoid arthritis, a crippling disease that eats away at the joints and causes severe pain and swelling, arenâ€™t receiving their much-needed, low-cost drugs that prevent deformity.
In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction.
Positive outcomes in rheumatoid arthritis (RA) are closely linked to early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs).
BURLINGTON, Mass., Oct.
SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%óˆž´% as compared with placebo.
BURLINGTON, Mass., Sept.
New criteria for rheumatoid arthritis (RA), published in the Annals of Rheumatic Diseases, could prevent thousands of people from developing disabling late stage disease, by redefining how RA should be classified.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.